Bonus BioGroup · raw details

Viable Tissue-regenerating Bone Grafts · Haifa · Founded 1981

active Public ← back to profile

Highlights

IIA supported (ever)1 patentProfile claimed by owner

About

Viable Tissue-regenerating Bone Grafts

Bonus BioGroup is a product-focused biotechnology company applying proprietary technology to supply tissue-regenerating, viable bone grafts. The company develops cell therapy and tissue-engineering products based on autologous bone implants that enable efficient bone transplantation and provide cell-based bone replacement for repairing bone lesions. Bonus BioGroup is the developer of BonoFill, a method for growing high-density 3D bone grafts based on multicell 3D cultures. BonoFill is derived from the patients own cells and constructed from a variety of cells grown in multiple layers within a bioreactor system. BonoFills technology enables the construction of bone grafts outside of the human body (ex vivo) and promotes graft acceptance by the patients body following transplantation. It also allows growth of a human tissue graft tailored to the biological, physical, and clinical needs of each patient, without incurring immune reactions or graft rejection.

Identity

NameBonus BioGroup
Slugbonus-biogroup
Type / kindstartup
Crunchbase IDbonus-biogroup
Source _idagxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ6boskKDA

Status

Statusactive
Status reasonPublic on TASE on Feb, 2012<br>
Last update2026-05-17

Location

HQ country codeIL
HQ region/districtNorth District
HQ cityHaifa
HQ addressNahum Het St 9, Haifa, Israel

Web & social

Websitehttps://www.bonus-bio.com
LinkedInhttps://www.linkedin.com/company/14822062
Twitter / Xhttps://twitter.com/BBiogroup
Facebookhttps://www.facebook.com/BonusBio
YouTubehttps://www.youtube.com/channel/UChXNkBN4lQ0QKLW1w1Dls_Q

Classifications

Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesHealthcarePatientsProvidersLife SciencesBiotechnology
Business models
B2B
Tags
biotechnologyregenerative-medicinebonemedical-technologiestissue-regeneration3d-technologycell-therapystem-cellspersonalized-medicineorthopedics

Funding

Total raised$25.6M
Current stagePublic
Market cap$96.4M

Raw source document

Show full JSON (0 KB)
{
  "0": "s",
  "1": "l",
  "2": "i",
  "3": "m",
  "4": "p",
  "5": "a",
  "6": "g",
  "7": "e",
  "8": "s",
  "9": "_",
  "10": "i",
  "11": "m",
  "12": "p",
  "13": "o",
  "14": "r",
  "15": "t"
}